Berberine Side Effects: What 60 Studies Report (2026 Evidence Grade)

Across 12 randomized trials that tracked adverse events, gastrointestinal symptoms occurred in 2 to 23 percent of berberine users versus 2 to 15 percent on placebo, and no trial reported a serious adverse event attributed to berberine (PMID 36941490). That is the reassuring half. The other half is a preclinical cardiac signal no supplement trial has monitored, an interaction list that overlaps heavily with the people most likely to take it, and a hard contraindication in pregnancy that most labels bury.

Presented By Our Partners

What the trials recorded

The cardiac signal nobody monitors

A 2025 systematic review of 22 studies found berberine inhibits hERG potassium channels and in preclinical models prolonged the QT interval, slowed heart rate and lowered blood pressure, alongside the antiarrhythmic effects it is sometimes sold for (PMID 40248925). Most of that evidence is animal and cell work. No supplement trial has run ECG monitoring on berberine users. The one clinical trial in a cardiac setting, 200 bypass-surgery patients, found berberine reduced postoperative atrial fibrillation with no excess mortality (PMID 36178742), which is reassuring for that population and silent on everyone else. The practical point is that anyone already taking a QT-prolonging drug, certain antiarrhythmics, antipsychotics and macrolide antibiotics among them, sits outside every trial population.

Interactions documented in the literature

Berberine inhibits CYP3A4 and CYP2C9. It raises cyclosporine blood levels in transplant recipients (PMID 15860440), a major interaction. A berberine-containing botanical reduced metformin exposure by up to 20 percent at low metformin doses through intestinal transporters, though glucose control still improved (PMID 39943692). Berberine stimulates glucose-dependent insulin secretion (PMID 34556670), so stacking it with insulin or sulfonylureas is additive in theory; those patients were excluded from most trials. Anticoagulant users were excluded too, because of CYP inhibition and reported antiplatelet activity. By contrast, six months of a berberine-silymarin product alongside half-dose statins produced no safety changes (PMID 25577665), and three trials in patients on antipsychotics found adverse events no different from placebo (PMID 34961418).

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Pregnancy, breastfeeding and infants

This is the one absolute line in the berberine literature. Berberine displaces bilirubin from albumin and crosses the placenta, which links it to neonatal jaundice and kernicterus risk, and it transfers into breast milk. Pregnant and breastfeeding women were excluded from every trial on this page, so there is no safety data, only the pharmacology that led to the exclusion.

What we do not know

Anything beyond 52 weeks: the longest trial ran one year with a combination product (PMID 28685558). Whether the QT signal matters at supplement doses, since plasma berberine in trials measured in the nanomolar range (PMID 31619442). Whether the single liver-enzyme elevation was chance. Whether the GI side effects differ between hydrochloride and enhanced-absorption forms.

Doses used in studies

These are doses reported by the named sources, not recommendations.

• The 2-year adenoma trial (PMID 31926918) used 300 mg twice daily; constipation 1 percent.
• The 6-month MASLD trial (PMID 41543854) used 1 g per day; adverse events matched placebo.
• The prediabetes pilot (PMID 37679692) used 500 mg three times daily for 12 weeks; no liver or kidney toxicity detected.

What this means for you

In trials, berberine’s side effect profile is mostly a gut profile, mild and often transient. The risks that matter are the ones trials did not test: drug interactions, pregnancy, and a cardiac rhythm signal from the lab bench. The full berberine evidence review carries the complete interaction table and the HYPE Index grades; the metformin comparison covers the diabetes-drug overlap.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.

Keep Reading on Healthcare Discovery

• New Science Study: Half Your Lifespan Is Genetic, Doubling Previous Estimates
• AI Found the Trial Patient. That Was the Easy Part.
• Beyond Weight Loss: The Mounting Evidence That GLP-1 Drugs May Be the First True Longevity Medications